Nucleic acid entrapment and delivery material with enzyme and pH responsiveness and preparation method thereof
By using amphiphilic zwitterionic monomers and enzyme-responsive crosslinking agents in the reverse phase fine emulsion polymerization system, the problem of stability and particle size control when cationic materials are loaded with nucleic acid molecules is solved, and high-efficiency packages are achieved loading and delivery, and nanogels exhibit excellent stability and biosafety in tumor treatment.
Patent Information
- Application Number
- CN202410859740.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-06-28
AI Technical Summary
Existing nucleic acid delivery materials have problems such as cationic toxicity, inflammatory reaction, poor stability of biomacromolecule/carrier complexes and difficulty in controlling particle size. Especially when cationic materials load nucleic acid molecules through positive and negative electrostatic action, the complex is unstable and particles. The diameter is uneven, making it difficult to achieve efficient packing and delivery.
The amphiphilic zwitterionic monomer is used to improve the reverse phase fine emulsion polymerization system, and nanogels are formed through interfacial polymerization, which improves the loading efficiency of nucleic acid molecules, and introduces enzyme-responsive crosslinking agents to impart the response of nanogel tumor matrix. , realize charge reversal and disintegration release in tumor cells.
It realizes efficient loading and delivery of nucleic acid molecules, improves loading and drug loading rates, and nanogels have excellent stability and biosafety, can effectively inhibit the expression of target genes, and show that it is shown in tumor treatment. Good performance.
Smart Images

Figure CN118949052A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of polymer chemistry and biomedical engineering, and more specifically, relates to a nucleic acid encapsulation and delivery material with enzyme and pH responsiveness and a preparation method thereof. Background Art
[0002] There are two main ways to deliver biomacromolecules: viral vectors and non-viral vectors. Due to the potential immunogenicity, random gene integration, limited loading capacity, high preparation cost and inability to deliver mRNA and protein drugs of viral vectors, their clinical application is limited. Non-viral delivery vectors are of great significance for the delivery of biomacromolecule drugs, but they also face some challenges:
[0003] 1. Cation toxicity and potential inflammatory response issues
[0004] Most nucleic acid delivery materials are cationic materials, which form nanoparticles by compounding nucleic acid molecules through positive and negative electrostatic interactions. In order to maintain the stability of the complex in the blood circulation, it is necessary to prepare nucleic acid nanoparticles at a higher N / P ratio, which not only leads to more residual positive charges on the nanoparticles, but also causes more free cationic materials in the composite system, which are the main sources of cationic toxicity of nucleic acid delivery materials. In addition, during the storage of nucleic acid / cationic complexes, due to kinetic instability, cationic materials will be dissolved, which also increases cationic toxicity. To this end, some strategies have been developed to try to reduce the risks of cationic toxicity, such as protonation of acid-sensitive groups under acidic conditions and deprotonation under neutral physiological conditions, loading nucleic acids under acidic conditions, and then using polymer chain crosslinking or hydrophobic aggregation to stabilize nanocomposites, so that nucleic acid-loaded nanoparticles are electrically neutral or weakly negatively charged under neutral conditions, thereby reducing toxic side effects on positive charges; cationic groups are connected to the main chain through acid-sensitive bonds, and after compounding nucleic acid molecules, disulfide bonds are used to crosslink and stabilize nanoparticles, and positively charged groups are dialyzed out under acidic conditions. Although these strategies can reduce the side effects of cationic toxicity to a certain extent, it is still difficult to circumvent cationic toxicity. In addition, cationic materials (including ionizable lipid particles) also have potential inflammatory response problems. Therefore, it is necessary to develop new strategies and materials for nucleic acid loading that do not rely on cationic components and positive and negative electrostatic interactions.
[0005] 2. In vivo stability of biomacromolecule / carrier complexes
[0006] Cationic polymers / lipid molecules load nucleic acid molecules through positive and negative electrostatic interactions. The entire loading process is a complex kinetic and thermodynamic process: competition between short-range electrostatic attraction (between nucleic acid and cationic material) and long-range electrostatic repulsion (between nucleic acid molecules); since the primary complex formed instantly after the nucleic acid and cationic material are mixed is not the state with the lowest free energy, many ring loop structures that are not electrically neutralized will be generated and will be adjusted over time. These complex processes cause secondary aggregation and phase separation precipitation of the complex, resulting in unstable particle size, uneven distribution and dissolution of free cationic polymer / lipid molecules. For example, the size of the complex formed by DNA / cationic material gradually increases over time. Due to the above complex process, the complex of nucleic acid molecules and cationic materials is affected by many factors. The complex of nucleic acid and cationic materials is not only related to the characteristics of N / P and the polymer itself (such as chemical composition, molecular weight, charge density, topological structure and hydrophobicity, etc.), but also to the order, method and speed of the mixing of the two. In addition, the ionic strength and pH value of the solvent also affect the formation of the complex. These make the complex a variable and difficult to accurately repeat process.
[0007] 3. Difficulty in particle size control
[0008] The particle size of the drug-loaded complex is of great significance to the blood circulation time, in vivo distribution, and deep tissue penetration of biomacromolecules; the width of the particle size distribution also plays a key role in improving the drug target tissue enrichment ability and reducing the side effects on normal tissues. Therefore, controlling the size of the particle size and its narrow distribution is crucial to improving the delivery ability of biomacromolecules. As mentioned above, the nucleic acid-loaded nanoparticles prepared based on cationic materials are unstable, resulting in difficult to control the particle size and uneven distribution. As for the biomacromolecule-loaded microcapsules prepared by the double emulsion method, the water phase spontaneously assembles into primary liposome particles during hydration, and its size and distribution do not meet the requirements. It needs to be post-processed by ultrasonication, homogenization, and membrane extrusion to obtain particles with uniform particle size. The processing steps are cumbersome, and the processing capacity of the nanoparticle size distribution is limited.
[0009] Existing research uses reverse miniemulsion polymerization to prepare nanogels for nucleic acid delivery. There are currently two common methods for preparing nanogels: direct crosslinking of polymers and heterogeneous polymerization of monomers and crosslinkers. The crosslinking of polymers is divided into physical crosslinking and chemical crosslinking. Physical crosslinking generally allows polymers to self-assemble in water through non-covalent bonds such as hydrophilic and hydrophobic interactions to form a crosslinked structure. The polymer chemical crosslinking method is a method for preparing nanogels by forming a crosslinked network between polymers through polymerization or other chemical reactions. The monomer polymerization method is a method of dispersing monomers and crosslinkers in an emulsion or reverse emulsion for polymerization to obtain a nanogel. This nanogel has high stability and loading capacity. It can not only load hydrophobic drugs, but also hydrophilic bioactive agents, and is widely used by researchers.
[0010] Inverse emulsion polymerization (IEP) is a heterogeneous polymerization method. It disperses the aqueous phase containing monomers and crosslinkers stably in the organic continuous phase under the action of surfactants and mechanical shear force to form a water-in-oil (W / O) dispersion system. After the addition of initiator, polymerization reaction occurs in the aqueous phase to form nanogel. Hydrophilic drugs can achieve higher loading effects due to the hydrophilic and hydrophobic effects. The design of the chemical structure of the crosslinker can also enable the gel to achieve different stimulus response functions.
[0011] As mentioned above, there are some insurmountable defects in assembling nucleic acid nanoparticles through positive and negative electrostatic interactions. Therefore, it is necessary to develop new strategies that do not rely on electrostatic loading of nucleic acid molecules. Reverse miniemulsion can encapsulate nucleic acid molecules in aqueous phase droplets, which provides the possibility for the development of new materials and methods that do not rely on electrostatic loading of nucleic acid molecules. Through reverse miniemulsion free radical polymerization, large molecular water-soluble nucleic acid molecules and small molecule chemical drugs can be encapsulated in nanogels, but the encapsulation efficiency of large molecular weight nucleic acid molecules is low, which is difficult to meet the requirements of practical applications. The reason is that: because the polymerization reaction begins at multiple centers inside the aqueous phase of the emulsion droplets, and there is no advantage in polymerization at the interface, the multiple cross-linked gel networks formed inside the aqueous phase are easy to squeeze nucleic acids out of the nanogel, resulting in low efficiency of nucleic acid encapsulation. At present, there is no literature report on related materials and methods that overcome the above-mentioned defects. Therefore, it is urgent to improve the material composition and preparation method of nanogel encapsulated nucleic acid molecules prepared by reverse miniemulsion polymerization to improve its encapsulation efficiency of nucleic acid molecules. Summary of the invention
[0012] The purpose of the present invention is to overcome the above-mentioned defects and shortcomings in the prior art and to provide a method for preparing a nanogel for loading and delivering nucleic acid molecules.
[0013] The second object of the present invention is to provide a nanogel material for loading and delivering nucleic acid molecules.
[0014] The above-mentioned object of the present invention is achieved through the following technical solutions:
[0015] The present invention first provides a method for preparing a nanogel material for loading and delivering nucleic acid molecules, comprising the following steps:
[0016] S1. dissolving the surfactant in an organic phase solvent to obtain an organic dispersion;
[0017] S2. dissolving the water-soluble monomer, the amphiphilic zwitterionic monomer, and the enzyme-responsive cross-linking agent in water to obtain an aqueous phase mixture;
[0018] S3. Adding the aqueous phase mixture into the organic dispersion to form an oil-in-water system, adding an initiator, and causing the oil-in-water system to undergo emulsion polymerization to form a nanogel.
[0019] The present invention introduces amphiphilic zwitterionic monomers into the reverse mini-emulsion polymerization system, thereby improving the monomer type. The introduced amphiphilic zwitterionic monomers can position more nucleic acid molecules at the interface, thereby quickly and preferentially forming a cross-linked network at the interface through the polymerization advantage of the interface, and constraining the nucleic acid molecules in the nanogel water phase core, thereby improving the nanogel encapsulation efficiency of nucleic acid molecules (encapsulation efficiency reaches 90.24%), and achieving efficient and safe encapsulation and delivery of nucleic acid molecules. Further, environmentally sensitive components can be introduced to give the nanogel tumor matrix responsive charge reversal and tumor cell disintegration and release of nucleic acid molecules, thereby improving the nanogel's loading and delivery capacity for nucleic acid molecules.
[0020] Furthermore, the nucleic acid molecule includes but is not limited to siRNA.
[0021] Furthermore, the surfactant in step S1 includes but is not limited to one or more of sodium bis(2-ethylhexyl)sulfosuccinate (AOT), Span-80, polyoxyethylene lauryl ether (Brij 30), and potassium monododecyl phosphate (MAEPK).
[0022] Preferably, the surfactant is sodium bis(2-ethylhexyl)sulfosuccinate (AOT) and Span-80.
[0023] Furthermore, the organic phase solvent in step S1 includes but is not limited to n-hexane, cyclohexane, isopentane, and dichloromethane.
[0024] Preferably, the organic phase solvent is n-hexane.
[0025] Furthermore, the water-soluble monomer in step S2 includes but is not limited to any one or more of 3-[(3-acrylamidopropyl)dimethylammonium] acetate (CBAA), 3-[N,N-dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]ammonium]propane-1-sulfonate (SBMA), and [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfonic acid propyl)ammonium hydroxide (DMAPS).
[0026] Preferably, the water-soluble monomer is 3-[(3-acrylamidopropyl)dimethylammonium]acetate (CBAA).
[0027] Furthermore, the amphiphilic zwitterionic monomer in step S2 includes but is not limited to any one or more of poly(diisopropylaminoethyl methacrylate)-poly(3-[(3-acrylamidopropyl)dimethylammonium] acetate-dimethylacetyl-methylacrylamine (PPAA), poly(diisopropylaminoethyl methacrylate)-polyethylene glycol-dimethylacetyl-methylacrylamine (PPGAA), and poly(diisopropylaminoethyl methacrylate)-poly(3-[N,N-dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]ammonium]propane-1-sulfonic acid inner salt)-dimethylacetyl-methylacrylamine (PPSBAA).
[0028] Preferably, the amphiphilic zwitterionic monomer is poly(diisopropylaminoethyl methacrylate)-poly(3-[(3-acrylamidopropyl)dimethylammonium]acetate)-dimethylacetyl-methylacrylamide (PPAA).
[0029] Preferably, the preparation method of the PPAA is as follows: using a raft reagent, 2-dodecyl trithiocarbonate-2-methylpropionic acid (DDAT), adding diisopropylaminoethyl methacrylate (DPA), and initiator azobisisobutyronitrile (AIBN), dissolved in a mixed solvent of DMF and water. Nitrogen protection is introduced at room temperature, and the reaction system is transferred to an oil bath for reaction, followed by addition of 3-[(3-acrylamidopropyl) dimethylammonium] acetate (CBAA) to continue the reaction. Cool to room temperature, add AIBN, bubbling nitrogen for 45 minutes, and then place at 70 ° C for reaction, and repeat the operation twice to remove the thiocarbonate group in the polymer. The reaction system is repeatedly precipitated twice in anhydrous ether, filtered, washed, and vacuum dried to obtain a white solid. Take the solid from the previous step, add 3-methylpropenamine, N-hydroxysuccinimide (NHS), N, N-dicyclohexylcarbodiimide (DCC), and add DMSO to react at room temperature. The white precipitate 1,3-dicyclohexylurea (DCU) in the reaction system was removed by filtration with an oily filter membrane. The obtained filtrate was precipitated in anhydrous ether, centrifuged, and the precipitate was washed twice with anhydrous ether. The precipitate was dried by vacuum for 12 hours to obtain a light yellow solid (PPAA).
[0030] Preferably, the structural formula of the PPAA is as shown in formula (I):
[0031]
[0032] Preferably, the PPGAA and PPSBAA can be synthesized by raft polymerization with reference to the PPAA synthesis steps.
[0033] Furthermore, the enzyme-responsive cross-linking agent in step S2 is a cross-linking agent that can be cleaved by an enzyme.
[0034] Furthermore, the enzyme-responsive cross-linking agent includes, but is not limited to, one or both of a cross-linking agent that can be cleaved by matrix metalloproteinase (MMP2) and a cross-linking agent that can be cleaved by cathepsin B (CTSB).
[0035] Preferably, the enzyme-responsive cross-linking agent is a cross-linking agent that can be cleaved by matrix metalloproteinase (MMP2) and a cross-linking agent that can be cleaved by cathepsin B (CTSB).
[0036] Preferably, in step S2, the mass ratio of the water-soluble monomer, the amphiphilic zwitterionic monomer, the cross-linking agent cleavable by matrix metalloproteinases, and the cross-linking agent cleavable by cathepsin B is 30:1:(0.1-0.5):2. More preferably, it is 30:1:0.25:2.
[0037] Preferably, the cross-linker (MP-CL) that can be cleaved by matrix metalloproteinases comprises the peptide segment: Ac-PLGLAGGKG-GKGGALGLP-Ac, wherein the amino acid sequence "PLGLA" can be cleaved and hydrolyzed by MMP2 enzyme, and a carbon-carbon double bond is introduced at the "K" position of lysine; the cross-linker (CB-CL) that can be cleaved by cathepsin B enzyme comprises the peptide segment: Ac-GLKGFLG KLG-NH2, wherein the amino acid sequence "GFLG" can be cleaved and hydrolyzed by cathepsin B, and a carbon-carbon double bond is introduced at the "K" position of lysine.
[0038] Preferably, the cross-linking agent that can be cleaved by matrix metalloproteinases has a peptide segment that is an inverted repeat sequence of a matrix metalloproteinase substrate.
[0039] Preferably, the cross-linker (MP-CL) cleavable by matrix metalloproteinases is synthesized by the following method: utilizing the amidation reaction between the primary amine in the polypeptide and the acyl chloride, mixing the MMP2 responsive polypeptide (sequence: Ac-PLGLAGGKG-GKGGALGLP-Ac) with methacryloyl chloride, adding DMSO to dissolve, stirring the reaction at room temperature overnight, dialyzing the reaction solution with methanol and ultrapure water in turn, taking the dialyzate and freeze-drying it, and finally obtaining white powder MP-CL.
[0040] Preferably, the structural formula of the MP-CL is as shown in formula (II):
[0041]
[0042] Preferably, the cross-linker (CB-CL) that can be cleaved by cathepsin B is synthesized by the following method: a CTSB enzyme-responsive polypeptide (sequence: Ac-GLKGFLGKLG-NH2) is mixed with methacryloyl chloride, DMSO is added to dissolve, the reaction is stirred at room temperature overnight, the reaction solution is dialyzed with methanol and ultrapure water in turn, the dialyzate is lyophilized, and finally a white powder CB-CL is obtained.
[0043] Preferably, the structural formula of the CB-CL is as shown in formula (III):
[0044]
[0045] Furthermore, the initiator in step S3 includes but is not limited to any one or any combination of ammonium persulfate and tetramethylethylenediamine (APS and TEMED), ammonium persulfate and sodium sulfite, azobisisobutyronitrile (AIBN), and azobisisobutylimidazoline hydrochloride (AIBI).
[0046] Preferably, the initiator is ammonium persulfate and tetramethylethylenediamine (APS and TEMED).
[0047] The present invention also provides a nano gel material prepared by the above-mentioned preparation method for loading and delivering nucleic acid molecules.
[0048] The present invention also provides a nanogel loaded with nucleic acid molecules and having triple responsiveness to MMP2 enzyme, CTSB enzyme and pH, which is based on the above-mentioned preparation method of the nanogel material for loading and delivering nucleic acid molecules, wherein step S2 is to dissolve water-soluble monomers, amphiphilic zwitterionic monomers, enzyme-responsive crosslinking agents, and nucleic acid molecules in water to obtain an aqueous phase mixture; the enzyme-responsive crosslinking agent is a crosslinking agent that can be cut and broken by matrix metalloproteinase MMP2 and a crosslinking agent that can be cut and broken by cathepsin B. The specific steps are as follows:
[0049] S1. dissolving the surfactant in an organic phase solvent to obtain an organic dispersion;
[0050] S2. dissolving water-soluble monomers, amphiphilic zwitterionic monomers, enzyme-responsive crosslinking agents, and nucleic acid molecules in water to obtain an aqueous phase mixture; the enzyme-responsive crosslinking agent is a crosslinking agent that can be cleaved by matrix metalloproteinase MMP2 and a crosslinking agent that can be cleaved by cathepsin B;
[0051] S3. Adding the aqueous phase mixture into the organic dispersion to form an oil-in-water system, adding an initiator, and causing the oil-in-water system to undergo emulsion polymerization to form a nanogel loaded with nucleic acid molecules.
[0052] Furthermore, the enzyme-responsive cross-linking agents are MP-CL and CB-CL.
[0053] Furthermore, the average particle size of the nanogel material is 60 to 70 nm.
[0054] Preferably, the average particle size of the nanogel material is 65 nm.
[0055] Furthermore, the nucleic acid molecule may be siRNA.
[0056] The above-prepared nanogel with triple responsiveness to MMP2 enzyme, CTSB enzyme and pH improves the reverse emulsion polymerization system with amphiphilic zwitterionic monomers, and simultaneously introduces two crosslinking agents (MP-CL and CB-CL) with responsiveness to MMP2 enzyme and CTSB enzyme, dissolves nucleic acid molecules in the aqueous phase, and finally forms nanogels by emulsion polymerization in the oil-in-water system by adding an initiator. The resulting nanogel interfacial crosslinking layer is a crosslinking structure of amphiphilic PPAA and enzyme-sensitive crosslinking agents (MP-CL, CB-CL), and the internal void portion can be used to load siRNA. Among them, amphiphilic zwitterionic monomers, MP-CL and CB-CL can synergistically enhance their ability to be taken up by cells, and the release of nucleic acid molecules from the nanogel is synergistically promoted in the environment of low pH, MMP2 and CTSB co-existing.
[0057] Furthermore, the siRNA includes but is not limited to siRNA that can effectively inhibit the expression of PLK1 gene. Taking siRNA targeting PLK1 as an example, the nanogel delivery material loaded with siRNA can efficiently deliver siRNA to cells, effectively inhibit the expression of PLK1 gene, and has excellent stability and biosafety.
[0058] The present invention provides use of any of the above-mentioned nanogel materials for loading and delivering nucleic acid molecules in the preparation of tumor therapeutic drugs.
[0059] The present invention also provides the use of the above-mentioned nanogel loaded with nucleic acid molecules and having triple responsiveness to MMP2 enzyme, CTSB enzyme and pH in the preparation of tumor therapeutic drugs.
[0060] Compared with the prior art, the present invention has the following beneficial effects:
[0061] The invention provides a nanogel with high efficiency encapsulation and delivery rate. The material can be used for high efficiency encapsulation and delivery of nucleic acid molecules. The preparation method thereof uses amphiphilic zwitterionic monomers to improve the reverse emulsion polymerization system, strengthen the polymerization at the interface of the two phases, avoid the extrusion effect of the polymerization in the inner core of the aqueous phase on the nucleic acid molecules, thereby improving the encapsulation efficiency of the nanogel on the nucleic acid molecules, and the encapsulation rate of the nanogel on siRNA reaches 90.24%, and the drug loading rate is about 1.60%. Further, crosslinking agents MP-CL and CB-CL that can break in response to matrix metalloproteinase II (MMP2) or cathepsin B (CTSB) are introduced, thereby giving the nanogel tumor matrix responsive charge reversal and the ability to disintegrate and release nucleic acid molecules in tumor cells. At the same time, the introduction of amphiphilic zwitterionic monomers, MP-CL and CB-CL can synergistically enhance the ability of the nanogel to be taken up by cells; the acid-sensitive block on the amphiphilic monomer enables the nanogel to have lysosomal escape ability. The delivery material can efficiently deliver siRNA to cells, effectively inhibit the expression of target genes, and has excellent stability and biosafety. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 The synthetic flow chart of MP-CL (a), CB-CL (b), and PPAA (c).
[0063] Figure 2 This is the NMR spectrum of the MMP2 enzyme-responsive cross-linker MP-CL.
[0064] Figure 3 This is the NMR spectrum of the CTSB enzyme-responsive cross-linker CB-CL.
[0065] Figure 4 This is the NMR spectrum of the amphiphilic molecule PPAA.
[0066] Figure 5 This is a transmission electron microscopy image of PMC-NG / siRNA.
[0067] Figure 6 is the standard curve of siRNA.
[0068] Figure 7 The in vitro simulated release curve of siRNA from PMC-NG / siRNA under different pH, MMP2 and CTSB conditions.
[0069] Figure 8 The graph shows the particle size potential results of nanogels with different MP-CL input amounts under different conditions (without MMP2 enzyme and with 10 nM MMP2 enzyme).
[0070] Fig. 9 This is a graph showing the stability results of the nanogel in simulated serum in vitro.
[0071] Fig.10 Confocal microscopy image (a) and flow cytometry image (b) of polymer nanogels incubated with cells for 4 hours.
[0072] Fig.11 Schematic diagram of the preparation and working process of siRNA-loaded nanogel.
[0073] Fig.12 The cytotoxicity results of empty nanogels of different concentrations on liver cancer cells SMMC7721 and normal human liver cells LO2 (a) and the cytotoxicity results of PMC-NG / siRNA and PMC-NG / SCR on liver cancer cells SMMC7721 and normal human liver cells LO2 (b).
[0074] Fig.13 Tumor volume curves of mice in different groups.
[0075] Fig.14 HE staining images of tumors (a) and major organ tissues (b) in different groups of mice. DETAILED DESCRIPTION
[0076] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0077] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0078] Example 1 Synthesis of Related Compounds
[0079] (1) Synthesis of MMP2 enzyme-responsive cross-linker (MP-CL): 0.1 g of MMP2 sensitive peptide (sequence: Ac-PLGLAGGKG-GKGGALGLP-Ac) and 0.11 g of methacryloyl chloride were added to a 25 mL eggplant-shaped bottle, and 10 mL of DMSO was added to dissolve. The reaction was stirred at room temperature overnight, and then the reaction solution was transferred to a dialysis bag (MWCO: 0.5 kDa), dialyzed with methanol for 24 h, and then dialyzed with ultrapure water for 24 h. The dialyzate was lyophilized to obtain a white powder (MP-CL). The synthesis process is as follows: Figure 1 (a) shown.
[0080] (2) Synthesis of CTSB enzyme-responsive cross-linker (CB-CL): Specifically, 0.10 g of polypeptide (containing GFLG sequence, the sequence is Ac-GLKGFLGKLG-NH2) and 0.101 g of methacryloyl chloride were added to a 25 mL eggplant-shaped bottle, 10 mL of DMSO was added to dissolve, and the reaction was stirred at room temperature for 12 h. The reaction solution was then transferred to a dialysis bag with a molecular weight cutoff (MWCO) of 0.5 kDa, dialyzed with methanol for 1 day, and then dialyzed with ultrapure water for 1 day. The dialyzate was lyophilized to obtain a white powder (CB-CL). The synthesis process is as follows: Figure 1 (b) as shown.
[0081] (3) Synthesis of amphiphilic molecule (PPAA): Specifically, weigh 0.5 g of 2-dodecyl trithiocarbonate-2-methylpropionic acid (DDAT) as a raft reagent, add 1.74 g of diisopropylaminoethyl methacrylate (DPA), and add 22.49 mg of initiator azobisisobutyronitrile (AIBN) into a 100 mL reaction bottle and dissolve in 50 mL of a mixed solvent of reaction-grade DMF and water (95:5, v / v). After nitrogen protection at room temperature for 45 min, the reaction system was transferred to a 70°C oil bath for reaction for 24 h, and then 0.43 g of 3-[(3-acrylamidopropyl)dimethylammonium]acetate (CBAA) was added and the reaction continued for 24 h. Then, the reaction was rapidly cooled to room temperature, 4.51 g of AIBN was added, nitrogen was bubbled for 45 min, and then the reaction was placed at 70°C for reaction for 24 h. This operation was repeated twice to remove the thiocarbonate groups in the polymer. After that, the reaction system was repeatedly precipitated twice in anhydrous ether, filtered, and the solid was washed with acetone and dried in vacuo to obtain a white solid. Then take 1g of the solid obtained in the previous step, add 0.071g 3-methylpropyleneamine, 0.144g N-hydroxysuccinimide (NHS), 0.258g N, N-dicyclohexylcarbodiimide (DCC), add 25mL DMSO, and react at room temperature for 24h. Subsequently, the white precipitate 1,3-dicyclohexylurea (DCU) in the reaction system was removed by filtration with an oily filter membrane. The obtained filtrate was precipitated in anhydrous ether, centrifuged, and the precipitate was washed twice with anhydrous ether. The precipitate was dried by vacuum for 12h to finally obtain a light yellow solid (recorded as PPAA). The synthesis process is as follows Figure 1 (c) as shown.
[0082] The obtained products were subjected to NMR analysis. The NMR spectra of MMP2 enzyme responsive crosslinker MP-CL, CTSB enzyme responsive crosslinker CB-CL, and amphiphilic molecule PPAA were as follows: Figure 2As shown in Figures 3 and 4, the main NMR peaks have a good assignment. According to the ratio of the NMR integral area of the carbon-carbon double bond hydrogen at the end of the PPAA main chain to the integral area of -CH3 hydrogen connected to the quaternary amine in the PCBAA segment repeating unit and the integral area of -CH(CH3)2 hydrogen connected to the tertiary amine in the PDPA segment, it can be calculated that the number of PCBAA repeating units is approximately 2 and the number of PDPA repeating units is 3.
[0083] Example 2 Preparation of siRNA-loaded nanogel PMC-NG / siRNA
[0084] Weigh sodium bis(2-ethylhexyl)sulfosuccinate (AOT, 160 mg) and Span-80 (Span-80, 640 mg); then add n-hexane (20-30 mL), stir vigorously until the surfactant is completely dissolved, and pass nitrogen for 10 minutes. Dissolve monomers CBAA (30 mg, dissolved in 150 μL water), PPAA (1 mg, dissolved in 500 μL water), CB-CL (2 mg, dissolved in 20 μL DMSO), MP-CL (0.25 mg, dissolved in 5 μL DMSO), and siRNA (33 μg, dissolved in 33 μL water) in water. Pass nitrogen into the aqueous phase for 5-10 minutes, then slowly add the aqueous phase mixture dropwise to the organic dispersion, stir for 5-10 minutes, and then add 15 μL of 20% ammonium persulfate (APS) solution to the aqueous phase. After stirring for 5 minutes, 8 μL of tetramethylethylenediamine (TEMED) was added to initiate the polymerization reaction, and rapid magnetic stirring was performed under ice-water bath conditions. After the reaction was continued for 2 hours, 3 times excess volume of pre-cooled acetone was added to precipitate the precipitate, which was placed in a -20°C refrigerator for 30 minutes, then washed with acetone 3 times, and vacuum dried for about 24 hours to obtain a freeze-dried product for storage or use. The nanogel was re-dissolved in PBS buffer at pH 7.4, centrifuged to obtain a clear liquid, and then purified with an ultrafiltration tube with a molecular weight cutoff of 100 KDa to remove free CBAA, siRNA, cross-linking agents and other molecular substances to obtain siRNA-loaded nanogel PMC-NG / siRNA.
[0085] The TEM morphology of nanogel PMC-NG / siRNA was characterized. Figure 5 As shown, the nanogel PMC-NG / siRNA morphology is a spherical structure with a particle size of approximately 65 nm.
[0086] Example 3 Determination of the encapsulation efficiency and drug loading rate of siRNA by nanogel PMC-NG / siRNA
[0087] Determination of siRNA content in the nanogel prepared in Example 2: The following absorbance values were obtained by using a Unico UV-2000 UV-visible spectrophotometer to detect the ultraviolet absorption of RNA at 260 nm. First, siRNA aqueous solutions with known mass concentration gradients (10, 15, 20, 25 and 30 μg / mL) were prepared, and the absorbance values were measured respectively. The standard curve of siRNA was prepared using origin simulation. The standard curve of siRNA is shown in FIG. Figure 6 Then a certain amount of siRNA-loaded nanogel was freeze-dried, and its mass was measured by an electronic balance, and then it was re-dissolved with 1 mL of water. The absorbance of the obtained solution was measured at 260 nm by a UV-visible spectrophotometer, and the mass of siRNA was calculated using the standard curve simulated above. The PMC-NG / siRNA sample was freeze-dried, and the sample mass was weighed after freeze-drying. At the same time, the siRNA-loaded nanogel without the introduction of PPAA was prepared and measured, and then the encapsulation efficiency and drug loading rate of the sample for siRNA can be calculated using the following formula:
[0088] The calculation method of siRNA encapsulation efficiency (LE) and drug loading rate (LC) is as follows: encapsulation efficiency (LE) = (mass of siRNA loaded on nanogel) ÷ (mass of siRNA input) × 100%, drug loading rate (LC) = (mass of siRNA loaded on nanogel) ÷ (mass of freeze-dried nanogel sample) × 100%. The encapsulation efficiency of nanogel for siRNA measured by the above method is 90.24%, and the drug loading rate is about 1.60%, while the encapsulation efficiency of nanogel for siRNA without the introduction of PPAA is only 61.25%, and the drug loading rate is 1.06%.
[0089] Example 4 PMC-NG / siRNA nanogel siRNA in vitro simulated release curve
[0090] First, the siRNA release experiment was divided into 10 groups (Group 1: pH 7.4 PBS; Group 2: pH 6.5 PBS; Group 3: pH 5.0 PBS; Group 4: pH 7.4, 10 nM MMP2; Group 5: pH 6.5, 10 nM MMP2; Group 6: pH 7.4, 1 mM papain; Group 7: pH 5.0, 1 mM papain; Group 8: pH 7.4, 10 nM MMP2 and 1 mM papain; Group 9: pH 6.5, 10 nM MMP2 and 1 mM papain; Group 10: pH 5.0, 10 nM MMP2 and 1 mM papain). The above solutions were all prepared using 50 mM PBS. First, assemble the nanogel according to the optimized conditions in the previous section, and then divide the samples into 10 groups, set 6 time points (0, 2, 4, 8, 12 and 24h) for each group, and divide the above 10 groups of solutions into 6 equal parts, and add the above solutions at the set time points. Finally, place it in a constant temperature shaker at 37°C to simulate the in vivo environment to test the release of the drug. Take out 2mL of buffer medium at the set time point and add fresh equal volume of PBS. The sample solutions obtained at each time point and all samples to be released for 24h are subjected to agarose gel electrophoresis experiments at the same time. The siRNA release amount at different time points in each group is obtained and released by grayscale analysis and calculation.
[0091] like Figure 7 As shown in the figure, at pH 7.4 and 6.5, the release rate of siRNA molecules from the nanogel was the lowest, and the cumulative release rate did not exceed 8% at the two pH levels after 24 hours of incubation. However, at pH 5.0, the release of siRNA increased to about 15%, which was attributed to the conversion of the PDPA block in PPAA from hydrophobic to hydrophilic due to the protonation of the tertiary amine group. At pH 6.5, the addition of MMP2 further increased the release rate of siRNA to about 20%, because the MP-CL in the gel was cleaved by the MMP2 enzyme, and the cross-linking agent was broken, which weakened the binding effect on siRNA to a certain extent, but because the proportion of MP-CL in the nanogel was not high, the release of siRNA in the nanogel was limited at this time. In contrast, at pH 7.4 and 6.5, the addition of CTSB enzyme increased the siRNA release rate to approximately 42% and approximately 50%, respectively. In the presence of both MMP2 and CTSB, the cumulative release rate of siRNA over 24 h at pH 5.0 exceeded 80%, indicating that low pH, MMP2, and CTSB synergistically promoted the release of siRNA from the nanogels.
[0092] Example 5 Particle size potential test of nanogels with different MP-CL dosage under different conditions (without MMP2 enzyme and with 10 nM MMP2 enzyme)
[0093] Referring to the method of Example 2, the amount of MP-CL input was changed (0.1 mg, 0.25 mg, 0.5 mg), and nanogels PMC-NG / siRNA loaded with siRNA (respectively recorded as NG 0.1, NG 0.25, and NG 0.5) were prepared. Three groups of nanogel samples were taken and divided into two equal parts, and 10 nM MMP2 enzyme solution and pH 7.4 PBS were added respectively. The hydrated particle size and Zeta surface potential were measured on a 90Plus / BI-MAS Zeta potential and particle size analyzer, and each sample was measured 3 times in parallel.
[0094] like Figure 8 As shown in the figure, the particle size of NG 0.1 and NG 0.25 is about 68-69nm, and the distribution uniformity is good, and the Zeta potential is about -1mV; while the particle size and potential distribution ratio of NG 0.5 is 473.43nm and -0.36mV, and the particle size distribution uniformity is poor, and the test results are unstable. The reason may be that the amount of MP-CL used is too large, resulting in a large degree of cross-linking of the polymer chain in the NG 0.5 structure, forming particles with large and uneven particle size. In addition, by investigating the effect of MMP2 enzyme on the surface potential of nanogels, compared with samples without MMP2 enzyme (-0.95mV, -1.19mV and -0.36mV), after adding 10nM MMP2 enzyme, the surface potential of NG0.1, NG 0.25 and NG 0.5 hydrogels turned to +6.52mV, +15.13mV and +22.40mV, respectively. This is attributed to the cleavage of MP-CL by the MMP2 enzyme. When the MMP2 enzyme cleaves the reverse-linked MMP2 substrate peptide, the primary amine group remains in the nanogel, while the end connected to the carboxyl group falls off, and the nanogel exhibits positive charge. This also verifies that the prepared nanogel has good MMP2 enzyme responsiveness and can respond to the high expression of MMP2 enzyme in the tumor matrix microenvironment to achieve charge reversal, thereby theoretically promoting the absorption of siRNA by tumor cells.
[0095] Example 6 Study on the stability of nanogel in simulated serum in vitro
[0096] With reference to the method of Example 2, empty nanogel PMC-NG without loading, nanogel PMC-NG-SCR loaded with common primer SCR, and nanogel PMC-NG-siPLK1 loaded with siRNA were prepared respectively. The changes of hydrated particle size of nanogel loaded drugs in simulated physiological environment (PBS+10% FBS) were measured by 90Plus / BI-MAS Zeta potential and particle size analyzer (Brookhaven, USA). 1 mg / mL of each group of nanogels was added to PBS with 10% FBS, and the hydrated particle size of each group was measured at different incubation times (4, 8, 12, 24 and 48 h).
[0097] like Fig. 9 As shown, under the condition of DMEM+10% FBS, the particle size of different groups of nanogels fluctuated between 55 and 74 nm within 50 hours, and the particle size did not change substantially. This is because the nanogels have good water solubility and biocompatibility, providing a basis for subsequent cell experiments and animal experiments.
[0098] Example 7 Study on Cellular Uptake and Intracellular Distribution of Polymer Nanogels
[0099] Referring to the method of Example 2, the loaded siRNA was replaced with a primer labeled with Cy3, and four experimental groups were prepared, including nanogel CB-NG-Cy3 without PPAA and MP-CL, nanogel PC-NG-Cy3 without MP-CL, nanogel MC-NG-Cy3 without PPAA, and nanogel PMC-NG-Cy3 containing PPAA, MP-CL and CB-CL, and PBS was used as the control group. The uptake of nanogel by tumor cells was observed by CLSM confocal electron microscopy. The specific steps were as follows: about 1×10 5 / mL concentration of SMMC7721 cells, were inoculated in each confocal culture dish with DMEM complete medium at pH 7.4 / mL, and then cultured overnight in a humidified incubator (37°C and 5% CO2). The next day, the same concentration of nanogel (50ng / mL) was incubated for 4h and then washed twice with PBS, Hoechst 33342 (5μg / mL) was added to incubate the cell nucleus for 15min, and the original medium was removed and washed 3 times with PBS. CLSM was used to observe the incubation of drugs and cells, the fluorescence of each group was photographed, and the efficiency of cell uptake of nanogels was detected by flow cytometry.
[0100] like Fig.10 As shown, in order to detect the uptake of siPLK1 loaded by the nanogel carrier by cells, the loaded primer nanogel PMC-NG-Cy3 was first designed to simulate and replace PMC-NG-siRNA for research experiments. First, the present invention first uses confocal detection results to show that Fig.10 Compared with the control group, the cells in the experimental group showed red fluorescence, and the red fluorescence intensity of the three groups of PPAA, MMP2 and CTSB enzyme sensitive peptides was significantly greater than that of other experimental groups. Flow cytometry was used to detect the uptake effect of different groups of Cy3 primer loaded nanogels at 4 hours, further confirming that the nanogels were taken up. Fig.10As shown, the control group and five groups of nanogel materials, CB-NG-Cy3, PC-NG-Cy3, MC-NG-Cy3, and PMC-NG-Cy3, were co-incubated with cells for 4 hours, and their uptake efficiency and fluorescence intensity were 0.27%, 23.1%, 55.84%, 73.4%, 94.3% and 1453±128, 5020±114, 7550±290, 12299±1592, and 20949±1366, respectively. Although different degrees of red fluorescence were detected in the cells of all nanogel-loaded primer Cy3 experimental groups, the nanogel of PMC-NG-Cy3 was taken up by the cells the most. This shows that when the same concentration of nanogel is used for incubation, the nanogel introduced with PPAA, MMP2, and CTSB enzyme-sensitive peptides can synergistically enhance the effect of cell uptake and drug release. On the one hand, the introduction of PPAA, due to its amphiphilicity, leads to its tendency to distribute at the oil-water interface during the process of nanogel formation, which increases the inner core voids of the gel to a certain extent and improves the loading efficiency of siRNA. On the other hand, amphiphilic PPAA can enhance the interaction between nanogel and cell membrane and facilitate the uptake by tumor cells. The introduction of two crosslinkers (MP-CL and CB-CL) responsive to MMP2 enzyme and CTSB enzyme enables nanogel to respond graded to MMP2 enzyme highly expressed in tumor tissue and CTSB enzyme in cells, enhancing the uptake and release of drugs. In tumor tissues where MMP2 enzyme is overexpressed, the peptide sequence of MP-CL breaks, a large amount of positive charge is exposed on the surface of nanodrugs, and the surface potential of nanoparticles turns positive, promoting the cell uptake of nanoparticles. After entering the cells, the CTSB enzyme-specific peptide constituting the crosslinking layer breaks in response to the CTSB enzyme highly expressed in lysosomes in tumor cells, and then releases siRNA from the nanogel. The tertiary amine of the PDPA block in the PPAA in the nanogel can respond to the acidic environment in the lysosome, promote the rupture of lysosomes through the proton sponge effect, and release siRNA. Schematic diagram of the preparation and working process of siRNA-loaded nanogel Fig.11 shown.
[0101] Example 8 Biosafety Evaluation of Nanogels and Cytotoxicity Detection of siRNA-Loaded Nanogels
[0102] Hepatoma cells (SMMC7721) and normal human liver cells (LO2) were cultured. The next day, the cells were washed twice with PBS and digested with 0.25% EDTA trypsin to form a cell suspension. The cell count concentration was about 3×10 4 / mL, and then 100μL / well was inoculated into a 96-well plate, with a cell density of about 3000 / well, and then cultured overnight under the same conditions, the original culture medium was removed, and the pre-configured empty nanogel (added according to a certain gradient polymer concentration) was added, and three replicates were seeded in each group. After the sample and cells were co-cultured for 48h, the culture medium was discarded, and 100μL of culture medium containing 5mg / mL MTT was added to each well, and the culture was continued for 4h under the same conditions, and then the culture medium was discarded, and 150μL of dimethyl sulfoxide DMSO was added to each well for oscillation and dissolution, and then the absorbance value at 570nm was measured by an enzyme marker, and finally the cell survival rate was calculated by the following method: Cell survival rate = (experimental group-blank background group) ÷ (control group-blank background group) × 100%. PMC-NG / siRNA, PMC-NG / SCR, etc., all used the same method to evaluate their cytotoxicity.
[0103] like Fig.12 As shown in (a), with the continuous increase of the empty nanogel concentration, the cell survival rate decreased slightly. When the polymer concentration was 50 μg / mL, the survival rates of LO2 and SMMC7721 cells were close to 100% and above 90%; even at a concentration of 200 μg / mL, the survival rates of LO2 and SMMC7721 cells were still as high as 90% and above 80%, respectively. These results indicate that the carrier itself has almost no toxicity to cells.
[0104] As Fig.12 As shown in (b), for PMC-NG / siRNA, with the increase of siRNA concentration, the effect of PLK1siRNA in inhibiting tumor cells is obvious. However, since PLK1 is also expressed in non-tumor cells, excessive siRNA will also have a certain impact on normal cells. In order to reduce its side effects and achieve the therapeutic effect on tumors, this study explored the reasonable range of siRNA concentration of about 4.5μg / mL. This concentration can not only kill tumor cells, but also minimize the damage to other normal cells.
[0105] Example 9 Treatment of siRNA-loaded nanogel in tumor-bearing mice
[0106] Tumor-bearing nude mice were randomly divided into 3 groups (PBS control group, PMC-NG / SCR group, PMC-NG / siPLK1 group), with 12 nude mice in each group. The drug was given every two days, and the long and short diameters of the tumor (the long diameter of the tumor a, the short diameter of the tumor b) were measured with a digital caliper after each administration, and the tumor volume was calculated using the formula: V = ab 2 / 2. When the tumor volume exceeds 2000mm 3 Or if they survive until the 39th day, they will all be euthanized.
[0107] Tumor tissue and major organs were removed and fixed with 4% paraformaldehyde. Major organs (heart, liver, spleen, kidney, lung) and tumors were collected and cut into paraffin sections for hematoxylin-eosin staining (HE). After staining, they were washed with running water, then separated with 1% dilute acid for 30 seconds and washed with running water, and then stained with eosin staining solution for 2 minutes and washed with running water; then the samples were immersed in 100%, 90%, 80% and 70% ethanol in turn, and hydrated for 5 minutes each time. Finally, the sections were dried and sealed with neutral glue, and photographed and recorded with a microscope.
[0108] like Fig.13 From the tumor growth curve of mice, it can be seen that the tumor volume of the PBS control group and the PMC-NG-SCR control group increased significantly. The average tumor volume reached 1800mm and 1800mm, respectively, after treatment on the 18th day. 3 With 1600mm 3 , while the mean volume of the PMC-NG-siPLK1 treatment group was only 600 mm 3 , which was different from the control group (p<0.05), indicating that the PMC-NG / siPLK1 treatment group had a certain inhibitory effect on mouse tumor growth.
[0109] In addition, from Fig.14 From the HE staining pictures of tumor tissues, we can see that high-density nuclei, clear interstitial cytoplasm, and tight connections between cytoplasms were observed in the PBS control group and the PMC-NG-SCR group, which is due to the high proliferation activity of tumor cells; in the PMC-NG / siPLK1 group, the morphology of tissue cells showed shallowly stained nuclei, rounded nuclei, or even reduced shrinkage, and the filling of interstitial fat tissue and widened intercellular gaps, indicating that the cells were in a state of apoptosis, indicating that PMC-NG / siPLK1 has an inhibitory effect on tumor growth in mice. No obvious pathological changes were observed in the tissues of the main organs (heart, liver, spleen, lung, and kidney) of the three groups of mice, indicating that the nanogel has good biosafety.
Claims
1. A method for preparing a nanogel for loading and delivering nucleic acid molecules, characterized in that: The following steps are involved: S1. dissolving the surfactant in an organic phase solvent to obtain an organic dispersion; S2. dissolving the water-soluble monomer, the amphiphilic zwitterionic monomer, and the enzyme-responsive cross-linking agent in water to obtain an aqueous phase mixture; S3. Adding the aqueous phase mixture into the organic dispersion to form an oil-in-water system, adding an initiator, and causing the oil-in-water system to undergo emulsion polymerization to form a nanogel.
2. The preparation method according to claim 1, characterized in that: The surfactant in step S1 is any one or more of sodium bis(2-ethylhexyl)sulfosuccinate, Span 80, polyoxyethylene lauryl ether or potassium monododecyl phosphate.
3. The preparation method according to claim 1, characterized in that: The organic phase solvent in step S1 is any one or more of n-hexane, cyclohexane, isopentane or dichloromethane.
4. The preparation method according to claim 1, characterized in that: The water-soluble monomer in step S2 is any one or more of 3-[(3-acrylamidopropyl)dimethylammonium]acetate, 3-[N,N-dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]ammonium]propane-1-sulfonic acid inner salt, and [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfonic acid propyl)ammonium hydroxide.
5. The preparation method according to claim 1, characterized in that: The amphiphilic zwitterionic monomer in step S2 is any one or more of polydiisopropylaminoethyl methacrylate-poly(3-[(3-acrylamidopropyl)dimethylammonium] acetate-dimethylacetyl-methylacrylamine, polydiisopropylaminoethyl methacrylate-polyethylene glycol-dimethylacetyl-methylacrylamine, and polydiisopropylaminoethyl methacrylate-poly(3-[N,N-dimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]ammonium]propane-1-sulfonic acid inner salt)-dimethylacetyl-methylacrylamine.
6. The preparation method according to claim 1, characterized in that: In step S2, the enzyme-responsive cross-linking agent is one or both of a cross-linking agent that can be cleaved by matrix metalloproteinase MMP2 and a cross-linking agent that can be cleaved by cathepsin B.
7. The nanogel material for loading and delivering nucleic acid molecules prepared by the preparation method according to any one of claims 1 to 6.
8. A nanogel loaded with nucleic acid molecules and having triple responsiveness to MMP2 enzyme, CTSB enzyme and pH, characterized in that: The nanogel is prepared by the preparation method of claim 1, wherein step S2 is to dissolve water-soluble monomers, amphiphilic zwitterionic monomers, enzyme-responsive crosslinking agents, and nucleic acid molecules in water to obtain an aqueous phase mixture; the enzyme-responsive crosslinking agent is a crosslinking agent that can be cut and broken by matrix metalloproteinase MMP2 and a crosslinking agent that can be cut and broken by cathepsin B.
9. The nanogel according to claim 8, characterized in that: The nucleic acid molecule is siRNA.
10. Use of the nanogel according to claim 8 or 9 in preparing tumor therapeutic drugs.
Citation Information
Patent Citations
Intelligent targeting and environmental dual-responsibility siRNA [short interfering RNA (ribonucleic acid)] delivery system for tumor, preparation method and application
CN106188555A
Zwitterionic polymer nanogel as well as preparation method and applications thereof
CN108379219A
Preparation method and application of stimuli-responsive poly-zwitterionic nanogel
CN114557958A
Esterase-responsive amphiphilic linear polymer as well as preparation method and application thereof
CN114605600A
Polymers and polymeric nanogels with hydrophilics encapsulation and release capabilities and methods thereof
US20170333363A1
